Astrazeneca Plc Stock Performance
| AZNCF Stock | USD 153.42 1.22 0.79% |
On a scale of 0 to 100, AstraZeneca PLC holds a performance score of 8. The firm shows a Beta (market volatility) of -0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning AstraZeneca PLC are expected to decrease at a much lower rate. During the bear market, AstraZeneca PLC is likely to outperform the market. Please check AstraZeneca PLC's expected short fall, day typical price, and the relationship between the potential upside and daily balance of power , to make a quick decision on whether AstraZeneca PLC's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, AstraZeneca PLC reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 6 B | |
| Free Cash Flow | 7.2 B |
AstraZeneca |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 13,092 in AstraZeneca PLC on December 21, 2024 and sell it today you would earn a total of 2,250 from holding AstraZeneca PLC or generate 17.19% return on investment over 90 days. AstraZeneca PLC is currently producing 0.3013% returns and takes up 2.7565% volatility of returns over 90 trading days. Put another way, 24% of traded pink sheets are less volatile than AstraZeneca, and 94% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
AstraZeneca PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AstraZeneca PLC's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as AstraZeneca PLC, and traders can use it to determine the average amount a AstraZeneca PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1093
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AZNCF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.76 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.3 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average AstraZeneca PLC is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AstraZeneca PLC by adding it to a well-diversified portfolio.
AstraZeneca PLC Fundamentals Growth
AstraZeneca Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Pink Sheet performance.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X | |||
| Price To Sales | 4.73 X | |||
| Revenue | 44.35 B | |||
| EBITDA | 9.33 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 2.11 X | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 6.38 B | |||
| Current Asset | 12.87 B | |||
| Current Liabilities | 15.38 B | |||
About AstraZeneca PLC Performance
By analyzing AstraZeneca PLC's fundamental ratios, stakeholders can gain valuable insights into AstraZeneca PLC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AstraZeneca PLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AstraZeneca PLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people.Things to note about AstraZeneca PLC performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for AstraZeneca PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity. |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's pink sheet. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AstraZeneca Pink Sheet analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |